German CRO joins tenants on Bayer campus
Bayer Healthcare’s Berlin site houses a CoLaborator building which rents space to small companies and start-ups. NMI TT will use one of the labs to offer its DigiWest multiplex protein profiling services. The platform can accelerate lead characterisation, disease mechanism and drug mode-of-action analyses, and perform biomarker identification projects for the pharma industry and academic projects.
The contract research organisation (CRO) said the office will improve NMI TT’s market position “by expanding its business activities beyond the existing well-established customer base.”
Proteomics
“We are very excited to start this new phase in our company’s development,” said Hugo Hämmerle, CEO.
“We see our expansion to Berlin as a unique opportunity to intensify our business development efforts across the international pharma and biotech market. This move also happens at a particularly promising time in the development of the proteomics field, which we are keen to help drive forward in the years to come, now through both our Reutlingen team and our new Berlin unit.”
NMI TT GmbH was founded in 2002 as a spin-out of the Natural and Medical Sciences Institute (NMI) at the University of Tübingen. It is headquartered in Reutlingen. Its Pharmaservices division offers biochemistry, protein profiling, molecular biology, and safety pharmacology.
Christoph Sachse, head of NMI TT’s Berlin operation, added “We expect that being closer to the needs of pharma R&D scientists and the lively Berlin biotech community will substantially help us in further developing and in marketing our wide range of contract research offerings, in particular our multiplex protein profiling platform, but also our capabilities in cellular assays and in generating customised cell lines.”
The CoLaborator building also houses labs for Calico GmbH, a recombinant monoclonal antibody developer; DexLeChem, which offers green catalysis and other chemical services; Eternygen, a start-up focused on dietary-related metabolic diseases; and Provitro AG, a molecular and pathological service provider for preclinical and clinical pharma research.
A second CoLaborator facility is based in San Francisco.
